Safety and Efficacy of Distal His Bundle Pacing Compared to Right Ventricular Pacing in Patients With Symptomatic Atrial Fibrillation Undergoing AV Node Ablation With Evidence of Heart Failure, a Randomised Control Study

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and estimates suggest its prevalence is increasing. Despite the advances in AF ablation strategies, the outcome of ablation procedures in persistent AF is still unsatisfactory. In addition, many patients are not candidates for ablation due to advanced age, comorbidities and previous failed ablation procedures. It is well known that there is no mortality benefit from rhythm versus rate control strategy in AF, therefore the increased number of AV node ablation and pacemaker insertion for patients with symptomatic AF with uncontrolled heart rate. Following AV node ablation, it is understandable that these patients will be paced 100% of the time where the value of physiological pacing will be at its most. The current standard practice is to pace the right ventricle for this cohort of patients unless they have severe LV systolic dysfunction when a biventricular pacing might be recommended. Previous data showed that RV pacing only can lead to deterioration of LV function, worsening of heart failure symptoms and increased mortality. HIS bundle pacing is a novel technique of pacing through placing the pacemaker lead on the junction box between the top and bottom chamber of the heart. This will allow the utilisation of the normal/intrinsic HIS Purkinjie (eclectic cables) to stimulate the ventricles. This can offer a physiological pacing modality and reduce pacing induced cardiomyopathy specially in pacing dependent pacing. The Ablate and Pace HIS Study proposes that the new method of HIS pacing is safe, effective and superior to the existing method of RV pacing in patients with atrial fibrillation who demonstrate signs of heart failure.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Aged 18 or above

• Symptomatic AF, New York Heart Association (NYHA) class II-IV

• Willing to consent for the study

• AF regardless type, deemed not suitable for rhythm control strategy that has been referred for AVN ablation with one of the following:

‣ Impaired LV function, EF \<50 %. And or

⁃ Raised N-Terminal Pro B-type Natriuretic Peptide ( NT-ProBNP) \>365 ng/L

Locations
Other Locations
United Kingdom
University Hospitals of Leicester NHS Trust
RECRUITING
Leicester
Contact Information
Primary
Mokhtar Ibrahim, Dr
mokhtar.ibrahim@uhl-tr.nhs.uk
0116 2583887
Time Frame
Start Date: 2023-11-24
Estimated Completion Date: 2026-09
Participants
Target number of participants: 100
Treatments
Active_comparator: Right Ventricular Only Pacing
All study participants will have an RV lead inserted, but this arm will have an RV lead only.
Other: HIS Bundle Pacing
Participants in this group will have HIS bundle pacing, but in addition will have an RV lead inserted that will serve as a backup alternative in the event HIS bundle pacing is not effective.
Sponsors
Leads: University Hospitals, Leicester
Collaborators: Medtronic

This content was sourced from clinicaltrials.gov